Exactly, Tony's tone was telling in that I don't genuinely believe that he considers Pfizer's offer to be approved by shareholders. Pfizer has helped the company to avoid a CR through the upfront $3m licensing agreement (plus $1m more based on milestones), so it's been a tactical decision by the Board. Read between the lines before considering selling and vote No.
Some great questions on the conference call - thank you to those holders who spoke up.
DYOR, GLTAH, IMO only
RAP Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held